7 hours ago 1

Crompton Greaves, Delhivery among 10 mid-cap stocks analysts expect to rally up to 53%

May 18, 2025, 01:06:27 PM IST

Brokerages remain optimistic about select mid-cap stocks across sectors, with several names showing strong analyst ratings and potential upside. According to Trendlyne data, 10 BSE Midcap index stocks — including Crompton Greaves, Dixon Technologies, Oil India, Delhivery, Cummins, and Aurobindo Pharma — are expected to deliver returns of up to 53%. Here's a look at the top picks:

iStock

Covered by 18 analysts, Aurobindo Pharma holds an average rating of 4.8 out of 5. The average target price is Rs 1,516, implying a 26% upside from the current level of Rs 1,201.

Agencies

ACC has coverage from 16 analysts with an average rating of 4.6. The average target price is Rs 2,642, suggesting a 37% potential upside from its current price of Rs 1,928.

ANI

With 13 analysts giving it a perfect average rating of 5, Crompton Greaves has an average target price of Rs 498, implying a 42% upside from the current price of Rs 351.

ETMarkets.com

Dixon Technologies holds an average rating of 4.6 from 13 analysts. The stock's average target price is Rs 20,077, reflecting a 21% upside from the current price of Rs 16,660.

ETMarkets.com

Covered by 11 analysts with an average rating of 5, Emami has a target price of Rs 831, indicating a 31% upside from the current market price of Rs 636.

Cummins is covered by 10 analysts with an average rating of 4.7. The stock’s average target price is Rs 3,829, suggesting a 26% upside from the current price of Rs 3,035.

ETMarkets.com

Oil India is also rated 5 on average by 10 analysts. The average target price is Rs 647, showing a 53% upside potential from the current market price of Rs 424.

Agencies

Rated 4.5 by 10 analysts, Delhivery has an average target price of Rs 426, indicating a 33% potential upside from the current price of Rs 321.

ETMarkets.com

Star Health holds an average rating of 4.6 from 9 analysts, with an average target of Rs 603, suggesting a 34% upside from the current price of Rs 451.

ANI

Ipca Laboratories is covered by 8 analysts with an average rating of 4.7. The stock has a target price of Rs 1,815, pointing to a 30% upside from the current market price of Rs 1,393.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)